PlainMeds provides educational information only. This is not medical advice. Always consult your doctor or pharmacist.

Drug side effects

valproate Side Effects

The reactions most often reported to the FDA for valproate (also sold as Depakote, Depakene), with demographics, serious outcomes, and reporting trends.

Data updated 2026-05-15

19,772
FAERS reports

Data from the FDA Adverse Event Reporting System (FAERS), 2001 to 2025. A FAERS report records a temporal association, not proof of cause. See our methodology for how figures are compiled and de-duplicated.

The most commonly reported side effects of valproate come from 19,772 reports to the FDA, broken down here by frequency, patient demographics, and serious outcomes.

This page analyzes 19,772 reports to the FDA Adverse Event Reporting System (FAERS) for valproate (Depakote): the reactions reported most often, who reported them, serious outcomes such as hospitalization, and year-over-year trends. A FAERS report does not prove the drug caused the effect, and report volume tracks how widely a drug is used, not how likely an effect is for any one person. Educational information, not medical advice.

Total Reports

19,772

Reports Mentioning Death

1,782

9.0% of reports — not proof the medicine caused the death

Hospitalizations

8,459

42.8% of reports

Top Indication

Product Used For Unknown Indication

Most Reported Adverse Reactions

DRUG INTERACTION
1,185
FOETAL EXPOSURE DURING PREGNANCY
1,043
SOMNOLENCE
950
EPILEPSY
813
TOXICITY TO VARIOUS AGENTS
757
SEIZURE
754
PYREXIA
738
CONVULSION
612
VOMITING
598
NEUTROPENIA
521
DIARRHOEA
520
WEIGHT INCREASED
502
CONDITION AGGRAVATED
500
NAUSEA
498
FATIGUE
489
ANXIETY
472
OVERDOSE
465
CONFUSIONAL STATE
454

Who Reports Side Effects

Gender Distribution

Female 8,291 (47%)
Male 9,279 (53%)
Unknown 76

Age Distribution

0-17 2,653 (19%)
18-44 4,890 (36%)
45-64 3,900 (28%)
65-74 1,373 (10%)
75+ 937 (7%)

Reporting Trend by Year

2001 2025

Reactions in Death Reports

Top reactions reported in 1,782 reports where death was an outcome. These are voluntarily reported and do not establish causation.

Reaction Reports
DEATH 237
SEPSIS 104
PNEUMONIA 101
CARDIAC ARREST 97
PYREXIA 88
TOXICITY TO VARIOUS AGENTS 87
DRUG INTERACTION 82
FOETAL EXPOSURE DURING PREGNANCY 82
MALAISE 73
VOMITING 71
STATUS EPILEPTICUS 67
CONVULSION 66
DIARRHOEA 66
COMPLETED SUICIDE 62
OVERDOSE 53
NAUSEA 51
CARDIO-RESPIRATORY ARREST 50
SUDDEN DEATH 50

Reactions in Hospitalization Reports

Top reactions in 8,459 reports where hospitalization was an outcome.

Reaction Reports
DRUG INTERACTION 595
PYREXIA 542
SOMNOLENCE 489
TOXICITY TO VARIOUS AGENTS 394
VOMITING 345
SUICIDE ATTEMPT 308
PNEUMONIA 304
EPILEPSY 297
SEIZURE 278
CONFUSIONAL STATE 277
OVERDOSE 272
DIARRHOEA 266
FALL 258
MALAISE 258
CONVULSION 257
WEIGHT INCREASED 256
THROMBOCYTOPENIA 245
HYPOTENSION 241

Compare valproate vs brivaracetam →

What the FAERS Data Reveals About valproate Side Effects

The FDA Adverse Event Reporting System (FAERS) contains 19,772 voluntary reports linked to valproate and its brand equivalents (Depakote, Depakene), spanning 2001 through 2025. Of those, 1,782 (9.0%) listed death as an outcome and 8,459 (42.8%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.

Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 47% were female and 53% male; age distribution skews toward 18-44, with 4,890 reports in that bracket. The single most reported reaction is drug interaction with 1,185 submissions, followed by foetal exposure during pregnancy and somnolence.

How to read these numbers

FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice, speak with a licensed clinician about any side-effect concerns.